Action Against AMD have partnered with artificial intelligence company BenevolentAI to uncover the mysteries of age-related macular degeneration.
Artificial intelligence has essentially been used to identify existing drugs that may reduce sight loss from macular degeneration. The initial results from the artificial intelligence project show a number of existing drugs have the potential to reduce sight loss from age-related macular degeneration, which is known to be the leading cause of sight loss.
Utilising artificial intelligence
Action Against AMD, a research collaboration formed by four UK sight loss charities (Blind Veterans UK, Fight for Sight, the Macular Society and Scottish War Blinded), partnered with artificial intelligence company BenevolentAI to carry out the research.
Benevolent AI used its ‘Benevolent Platform’ to comprehensively review and understand the millions of scientific papers, clinical trials information, and additional datasets relating to age-related macular degeneration with a view to identifying potential gene targets and treatments.
The research identified seven existing drugs – either already in development or being used to treat other conditions – that have the potential to be repurposed to enable healthy ageing and treat age-related macular degeneration. In addition, the analysis identified new gene targets for investigation.
Action Against AMD will now be taking the insight from the project to identify which drugs and gene targets are a priority for further investigation.
What do you know about age-related macular degeneration?
Age-related macular degeneration (AMD) is the leading cause of sight loss and can result in complete loss of central vision, with an estimated prevalence of 196 million people worldwide.
There are currently no approved treatments for the 95% of patients with early and ‘dry AMD’, although there are treatments for the 5% of patients with ‘wet AMD’ caused by new blood vessel growth – if caught early enough.
Dr Wen Hwa Lee, Chief Executive for Action Against AMD said: “It’s really promising that we have identified current drugs that may have a positive effect on macular degeneration. Our next step will be to confirm which of these drugs have the potential to slow progression of the disease and reduce sight loss for people with this condition.”
Dr Jackie Hunter, Board Director at BenevolentAI commented: “It has been a very productive partnership with Action Against AMD and we are delighted to have contributed some promising new research in age-related macular degeneration. I very much look forward to seeing the results of this research as it is developed further by Action Against AMD”.